News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sequenta, Inc. Expands Sample Types Accepted for ClonoSIGHT™ MRD Test for Leukemia and Lymphoma


9/25/2013 9:21:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta, Inc. today announced that the sample types eligible for analysis with its ClonoSIGHTâ„¢ minimal residual disease (MRD) test for leukemia and lymphoma have been expanded to include formalin-fixed, paraffin-embedded (FFPE) tissue and bone marrow aspirate slides. This advancement allows the test to be performed on the diagnostic samples most commonly available from pathology labs.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Lymphoma
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES